Show simple item record

dc.contributor.authorHande, Liv Nesse
dc.contributor.authorThunhaug, Hilde
dc.contributor.authorEnebakk, Terje
dc.contributor.authorLudviksen, Judith K
dc.contributor.authorPettersen, Kristin
dc.contributor.authorHovland, Anders
dc.contributor.authorLappegård, Knut Tore
dc.date.accessioned2020-03-18T08:55:34Z
dc.date.available2020-03-18T08:55:34Z
dc.date.issued2019-08-29
dc.description.abstract<i>Background</i> - Prestatin trials reported positive effects of omega-3 polyunsaturated fatty acids (n-3 PUFA) in cardiovascular disease, whereas recent studies and meta-analyses have not reproduced these results. The effect of n-3 PUFA in patients with familial hypercholesterolemia (FH), a group with particularly high risk of cardiovascular disease, is not well established.<p><p> <i>Objective</i> - We investigated the effect of n-3 PUFA in the early stage of atherosclerosis in FH patients by evaluating in vivo (peripheral arterial tonometry [PAT]) and in vitro (plasma asymmetric dimethylarginine and E-selectin) endothelial function.<p><p> <i>Methods</i> - This was a double-blind, placebo-controlled cross-over study with 34 FH patients on statin treatment (mean age 46.6 years). In random order, all individuals were treated for 3 months with high-dose n-3 PUFA (2 g, ×2) and 3 months placebo (olive oil, 2 g ×2), separated by a 3-month washout period. Anthropometric data, blood samples, and PAT were collected at 4 time points.<p><p> <i>Results</i> - There were no significant changes in reactive hyperemia index measured by PAT after n-3 PUFA compared with placebo, median reactive hyperemia index after n-3 PUFA was 1.98 and after placebo 1.96 (<i>P</i> = .51). No significant changes were detected in the soluble endothelial marker asymmetric dimethylarginine (in 2 different assays) when comparing n-3 PUFA and placebo (<i>P</i> = .92 and .14, respectively). Finally, the level of E-selectin did not change significantly during the trial (<i>P</i> = .26).<p><p> <i>Conclusion</i> - Addition of n-3 PUFA to standard lipid-lowering treatment in genetically verified FH patients did not affect the in vivo endothelial function or soluble endothelial markers.en_US
dc.descriptionAccepted manuscript version, licensed <a href=http://creativecommons.org/licenses/by-nc-nd/4.0/> CC BY-NC-ND 4.0. </a>en_US
dc.identifier.citationHande LN, Thunhaug H, Enebakk T, Ludviksen JK, Pettersen K, Hovland AW, Lappegård KT. Addition of marine omega-3 fatty acids to statins in familial hypercholesterolemia does not affect in vivo or in vitro endothelial function. Journal of Clinical Lipidology. 2019:1-9en_US
dc.identifier.cristinIDFRIDAID 1739243
dc.identifier.doi10.1016/j.jacl.2019.08.004
dc.identifier.issn1933-2874
dc.identifier.issn1876-4789
dc.identifier.urihttps://hdl.handle.net/10037/17783
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalJournal of Clinical Lipidology
dc.rights.accessRightsopenAccessen_US
dc.rights.holder© 2019 National Lipid Association. All rights reserved.en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleAddition of marine omega-3 fatty acids to statins in familial hypercholesterolemia does not affect in vivo or in vitro endothelial functionen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record